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Background: Breast cancer (BC) is the most frequent cancer in women, accounting for 28% of all tumors among
women in Catalonia (Spain). Mastectomy has been replaced over time by breast-conserving surgery (BCS) although
not as rapidly as might be expected. The aim of this study was to assess the evolution of surgical procedures in
incident BC cases in Catalonia between 2005 and 2011, and to analyze variations based on patient and hospital
characteristics.
Methods: We processed data from the Catalonian Health Service’s Acute Hospital Discharge database (HDD)
using ASEDAT software (Analysis, Selection and Extraction of Tumor Data) to identify all invasive BC incident
cases according to the codes 174.0-174.9 of the International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) that were attended for the one-year periods in 2005, 2008 and 2011. Patients were
classified according to surgical procedures (BCS vs mastectomy, and immediate vs delayed reconstruction), and
results were compared among periods according to age, stage, comorbidity and hospital level.
Results: BC surgical procedures were performed in more than 80% of patients. Surgical cases showed a significant
increasing trend in the proportion of women aged 50–69 years, more advanced disease stages, higher comorbidity
and they were attended in hospitals of less complexity level throughout the study period. Similar pattern was
found for patients treated with BCS, which increased significantly from 67.9% in 2005 to 74.0% in 2011.
Simple lymph node removal increased significantly (from 48.8% to 71.4% and from 63.6% to 67.8% for 2005 and
2011 in conservative and radical surgery, respectively). A slightly increase in the proportion of mastectomized
young women (from 28% in 2005 to 34% in 2011) was detected, due to multiple factors. About 22% of women
underwent post-mastectomy breast reconstruction, this being mostly immediate.
Conclusions: The use of HDD linked to the ASEDAT allowed us to evaluate BC surgical treatment in Catalonia.
A consolidating increasing trend of BCS was observed in women aged 50–69 years, which corresponds with the
pattern in most European countries. Among the mastectomized patients, immediate breast reconstructions have
risen significantly over the period 2005–2011.
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Breast cancer (BC) remains one of the most common
tumors in western countries, accounting for around
25-30% of cancers among women [1], in addition to
being one of the leading causes of death in these popula-
tions. The steady rise in incidence over the past decades
is attributable to the increased prevalence of certain risk
factors (such as hormone replacement therapy in meno-
pause) and the aging population. Improved diagnostic
capabilities, in the form of mammography screening,
also account for a spike in incidence [2,3].
In Spain, the incidence in women over 45 years has
stabilized since 2001 due to screening saturation; this
phenomenon is clearly observed where breast screening
programs were implemented before the year 2000 and
had high participation rates [4]. Among younger
women, the incidence is increasing, probably reflecting
lifestyle changes in these generations [5]. On the other
hand, mortality has declined since the 1990s mainly
due to earlier detection of tumors and therapeutic
advances [6,7].
In 2007, the age-adjusted incidence and mortality rates
in Catalonia (67.5 and 11.1 per 105 person-years, re-
spectively) [8] were below the European Union average
(77.1 and 16.6 cases per 105 person-years, respectively),
but above the Spanish average (61.0 and 12.9 per 105
person-years, respectively). As in the rest of the country,
however, indicators have improved: incidence has stabi-
lized, and mortality has decreased by 3.7% a year since
the early 1990s. The five-year relative survival rate was
81% for women diagnosed in 1995–1999, in comparison
to 76% for the 1990–1994 period [9].
Surgical resection remains the main treatment for BC.
However, in recent years there have been significant ad-
vances in breast-conserving surgery (BCS), which have
optimized treatment success when combined with radi-
ation and hormone therapy. As a result of this and early
detection, a large proportion of women have been able
to benefit from minimally invasive surgical techniques
for the breast and axilla since the turn of the century.
Monitoring of surgical procedures among breast cancer
patients would allow public health authorities to eva-
luate the implementation of cancer clinical practice
guidelines and the quality of treatments carried out in
hospitals [10].
The present study examines the surgical procedures
for incident cases of BC that were diagnosed over the
three, one-year periods in Catalonia (2005, 2008 and
2011), using the regional population-based database of
hospital discharges. Data were analyzed according to
socio-demographic (hospital level) and clinical (age,
comorbidity and clinical stage) characteristics, with the
aim of defining dictionaries and algorithms enabling us
to automate the collection of indicators.Methods
Data source
We used the Acute Hospital Discharge Dataset (HDD),
which includes records for all inpatient admissions from
public and private hospitals in Catalonia. This database
includes all episodes of healthcare in Catalonian health
centers that led to patient admission into modalities
including conventional hospitalization, major same-day
surgery, outpatient day hospital and domiciliary hospi-
talization [11]. Data for the 2003–2012 time period were
made available by the Catalonian Health Service, Health
Department of the Catalonian Government.
From the HDD, BC cases were identified on the basis
of the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) through the
ASEDAT software [12]. ASEDAT was developed follo-
wing the International Agency for Research on Cancer
(IARC) recommendations [13]. Based on computer al-
gorithms, it was designed to automatically detect and
extract incident cancer cases from different databases,
including the HDD in a given study period, with the
purpose of increasing data reliability and reduce costs
associated with a cancer registry.
We included women diagnosed with invasive breast
cancer (i.e., malignant neoplasm of female breast; ICD-
9-CM codes: 174.0-174.9) [14]. Data related to patients
with in situ breast carcinoma (ICD-9-CM code 233.0)
were excluded.
Identifying hospital episodes of care for breast cancer
patients
Administrative hospital discharge abstracts from these
BC cases were used to appropriately identify and con-
struct the complete hospital episodes belonging to each
patient. Patient abstracts were sorted in ascending order
according to date of admission and discharge date, in
that order.
Hospital episodes were defined by grouping together
consecutive abstracts that were closely related in time
(i.e., <24 hrs between them) and involved in a con-
tinuous healthcare process such as inter-hospital and
intra-hospital transfers.
Patients were identified by their valid Personal Health
Identification Numbers (the social security number),
which were used to match hospital abstracts with indivi-
dual patients. These data were pulled from the Catalonian
HDD from 2003 onwards, enabling us to identify and
compile all the different public hospital discharges where
an individual had been attended. The result for each pa-
tient was one or more hospital episodes, each constructed
from the corresponding hospital abstracts.
Episodes of inpatient care attended in private health
centers were excluded from the analysis, because private
hospitals do not use the Personal Health Identification
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them within the public health system. Prevalent cases,
defined as those with evidence of breast disease prior to
the respective study periods, were also excluded by
ASEDAT.
Defining the population and the breast cancer
procedures carried out
In summary, we used the Catalonian HDD to identify all
women with incident invasive BC diagnosed and
attended during the years 2005, 2008 and 2011.
We only examined three one-year periods because of: 1)
about 40% cases (1200 cases per year) remained unsolved
after applying ASEDAT for the whole period, and they
need to be manually checked by reviewing computer me-
dical records, making it unfeasible; 2) the reported years
are equidistants; and 3) data available for the time period
2003–2012 allow us to discard prevalent cases and ensure
the minimum 12-month follow-up for incident BC cases.
For each woman, an index surgical procedure (BCS or
mastectomy) was identified, as were subsequent surgical
procedures related to breast reconstruction that took
place within 12 months. Primary BCS and radical surgery
procedures were identified based on the ICD-9-CM. Like-
wise, we also considered other related procedures such as
removal of lymphatic structures (simple or radical), and
reconstruction (immediate or delayed) (Additional file 1:
Table S1). Immediate breast reconstruction was defined as
the presence of reconstructive surgery either as a primary
or as a secondary procedure that took place simulta-
neously within the same first surgical episode as the mast-
ectomy. Delayed reconstruction was limited to procedures
performed within 12 months after the mastectomy. Ac-
cording to the ICD-9-CM codes used, our patients did not
undergo any procedures of BCS or mastectomy during
the three one-year study periods were classified as non-
surgical.
Hospitals were categorized into three groups accor-
ding to the Catalonian Health Service classification:
i) high technology, including health centers providing
highly specialized services, ii) reference hospitals and iii)
county hospitals. In addition, the Charlson Comorbidity
Index (CCI) [15], was calculated taking into account all
the main and secondary diagnoses for the previous and
reference principal episode.
Results were analyzed according to (a) age groups
(≤49, 50–69 and ≥70 years old); (b) stage of disease at
diagnosis (using ICD-9-CM coding as a proxy) [16,17]
(Additional file 1: Table S2a); (c) hospital complexity;
and (d) comorbidity. Three levels of comorbidity were
defined according to Quan’s update of the CCI, as
applied to ICD-9-CM [18]: no comorbidity = 0, low co-
morbidity = from 1 to median truncated to 1, and high
comorbidity = more than the median truncated to 1.Tumor stage was classified as local (confined within
the breast), regional (affecting the lymph nodes, pri-
marily those in the armpit and/or upper arm) or distant
(the cancer is found in other parts of the body as well).
Hospital discharge ICD-9 codes were mapped using the
American Joint Committee on Cancer (AJCC) stages
[17] (Additional file 1: Tables S2a and S2b).
Statistical analysis
For each variable considered in the analysis, trends in
proportions during the years 2005, 2008 and 2011 were
assessed using a log-binomial regression model [19]. The
sign of the slope of this model (β) indicates if there was
an increasing (positive) or decreasing (negative) trend in
the proportions [19]. Statistical analyses were carried out
through the statistical software R [20] assuming a signifi-
cance level of α = 0.05.
Ethics
The study uses retrospective data from administrative
databases in where patients are anonymus to the re-
searchers and did not require informed consent nor
Ethics Committee approval.
Results
As shown in Table 1, the number of patients identified
with incident BC in 2005, 2008 and 2011 were 3739, 3849
and 3873 respectively, of whom 2971 (79.5%), 3218 (83.6%)
and 3330 (86%) underwent surgery in the Catalonian
public health system. It is worth noting that there were sta-
tistically significant increases in the proportions of BC sur-
gically treated.
Over the years, we found a significant increase of pro-
portion of women aged 50–69 among surgical cases (from
45.2% in 2005 to 47.0% in 2008 and finally 49.3% in 2011).
There were also increases in the percentage of patients
presenting with regional tumor stage (7.6%, 11.8% and
17.5% respectively) and distant tumor stage at diagnosis
(1.1%, 1.3% and 1.9%). The proportion of patients who
presented with comorbid diseases increased among those
with both low comorbidity (12.6%, 13.7% and 14.6%) and
high comorbidity (3.6%, 3.9% and 5.1%) (Table 1).
The percentage of BC patients who did not undergo
surgery is around 17% for the entire period. Regardless
of the year, non-surgical compared to surgical patients
showed more advanced disease at diagnosis, greater co-
morbidity, more frequent admittance through the emer-
gency department and in low complexity health centers
(county hospitals), more home healthcare requirements,
and higher 30-day mortality (Table 1).
Conservative or radical surgery
In 2011 in Catalonia, BCS accounted for 74% of BC sur-
gery, a significant increase in comparison to 2005 and
Table 1 Characteristics of breast cancer patients diagnosed in 2005, 2008 and 2011 in Catalonia, Spain, according to surgical treatment
SURGERY NO SURGERY
2005 2008 2011 2005 2008 2011
n (%) n (%) n (%) β* (95% CI) n (%) n (%) n (%) β* (95% CI)
Age
≤49 795 (26.8) 915 (28.4) 876 (26.3) −0.003 (−0.017; 0.010) 119 (15.5) 101 (16.0) 83 (15.3) −0.001 (−0.044; 0.041)
50 - 69 1344 (45.2) 1511 (47.0) 1642 (49.3) 0.014 (0.006; 0.023) 266 (34.6) 215 (34.1) 182 (33.5) −0.005 (−0.031; 0.020)
≥ 70 832 (28.0) 792 (24.6) 812 (24.4) −0.023 (−0.037;-0.009) 383 (49.9) 315 (49.9) 278 (51.2) 0.004 (−0.014; 0.022)
Stage
Local 2713 (91.3) 2794 (86.8) 2685 (80.6) −0.020 (−0.023;-0.017) 474 (61.7) 370 (58.6) 328 (60.4) −0.004 (−0.020; 0.010)
Regional 226 (7.6) 381 (11.8) 582 (17.5) 0.137 (0.114; 0.160) 24 (3.1) 14 (2.2) 15 (2.8) −0.027 (−0.140; 0.081)
Distant 32 (1.1) 43 (1.3) 63 (1.9) 0.096 (0.027; 0.167) 270 (35.2) 247 (39.1) 200 (36.8) 0.009 (−0.015; 0.032)
Charlson Comorbidity Index
No comorbidity 2490 (83.8) 2651 (82.4) 2674 (80.3) −0.007 (−0.011;-0.003) 545 (71.0) 405 (64.2) 339 (62.4) −0.023 (−0.036; −0.010)
Low comorbidity 375 (12.6) 440 (13.7) 485 (14.6) 0.024 (0.003; 0.045) 135 (17.6) 119 (18.9) 113 (20.8) 0.028 (−0.010; 0.065)
High comorbidity 106 (3.6) 127 (3.9) 171 (5.1) 0.063 (0.023; 0.103) 88 (11.5) 107 (17.0) 91 (16.8) 0.062 (0.019; 0.105)
Hospital complexity
Low 481 (16.2) 560 (17.4) 619 (18.6) 0.023 (0.005; 0.041) 196 (25.5) 149 (23.6) 133 (24.5) −0.008 (−0.040; 0.024)
Medium 1297 (43.7) 440 (45.3) 485 (48.4) −0.024 (−0.240;-0.207) 341 (44.4) 284 (45.0) 252 (46.4) 0.007 (−0.013; 0.027)
High 1193 (40.2) 127 (37.3) 171 (33.0) −0.468 (−0.496;-0.440) 231 (30.1) 198 (31.4) 158 (29.1) −0.004 (−0.032; 0.023)
Emergency admission 85 (2.9) 104 (3.2) 101 (3.0) 0.009 (−0.038;0.055) 388 (50.5) 379 (60.1) 334 (61.5) 0.032 (0.017; 0.048)
In-hospital deaths1 5 (0.2) 1 (0.0) 3 (0.1) −0.133 (−0.429;0.137) 80 (10.4) 80 (12.7) 59 (10.9) 0.010 (−0.041; 0.061)
Discharge destination
Domicile 2951 (99.3) 3200 (99.4) 3299 (99.1) 0 (−0.001;0.001) 659 (85.8) 496 (78.6) 414 (76.2) −0.021 (−0.031;-0.012)
With support 17 (0.6) 15 (0.5) 30 (0.9) 0.089 (−0.015;0.195) 43 (5.6) 61 (9.7) 77 (14.2) 0.152 (0.095; 0.210)
Other2 3 (0.1) 3 (0.1) 1 (0.0) −0.168 (−0.520;0.141) 66 (8.6) 74 (11.7) 52 (9.6) 0.021 (−0.033; 0.076)
Total3 2971 (79.5) 3218 (83.6) 3330 (86.0) 0.013 (0.009; 0.016) 768 (20.5) 631 (16.4) 543 (14.0) −0.064 (−0.081;-0.048)
*β is the slope of the log-binomial model used to measure the temporal trend; 95% CI: 95% Confidence Interval; In bold, statistically significant;
1Mortality within 30 days after admission; 2Includes hospital mortality during hospitalization (in-hospital mortality); 3Percentages were calculated taking into account the total number of patients (surgical and
non-surgical) in the respective years.
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(49.8%, 52.7% and 54.5% in 2005, 2008 and 2011, re-
spectively) and among women with presenting with
regional tumor stage (7.6%, 10.7% and 16.2%).
In high-tech hospitals, a significant decrease in the
percentage of patients treated with BCS (40.5%, 36.1%
and 32.6%) was observed, contrary to the trend observed
in health centers of medium (44.2%, 45.8% and 48.4%)
and low complexity (15.3% to 18.1% and 18.9%), where
it significantly increased (Table 2).
Likewise, a significant drop in radical surgery was ob-
served in the same period (from 32.1% in 2005 to 26.0%
in 2011), mainly in patients over 50 years old. On the
other hand, we detected a significant rise in mastecto-
mies in younger women (from 28.0% to 33.8%). Accor-
ding to the disease stage, there is a clear decline over
time in the practice of mastectomy in cases of local
disease (from 90.7% to 74.5%) and a significant increase
for regional (from 7.7% to 21.2%) and metastatic tumors
(from 1.7% to 4.3%). The most common modality of ra-
dical breast surgery was, by far, the simple mastectomy
(around 85% of all mastectomies throughout the study
period); radical mastectomy and subcutaneous mastec-
tomy followed at a considerable distance (Table 2).
Lymph node surgery in BCS significantly increased
(from 77.1% in 2005 to 86.2% in 2011), with important
advances in simple lymph node dissection (from 48.8%
to 71.4%). In mastectomized women, removal of lymph
nodes remained stable throughout time at around 88%,
and we detected a significant increase of simple lymph
node excisions.Mastectomy and immediate reconstruction
Around 22% of mastectomized patients underwent
breast reconstructive surgery in the Catalonian public
health system (17.1%, 25.3% and 22.8% in 2005, 2008
and 2011, respectively). This percentage increased sig-
nificantly in women with regional stage cancer (8.6%,
21.4% and 21.2% respectively), and in those who were
intervened in reference hospitals (28.8%, 34.4% and
42.9%). Furthermore, the proportion of delayed recon-
struction declined significantly (22.7%, 14.3% and 5.6%)
(Table 3).Discussion
According to the information obtained from the HDD,
more than 80% of invasive BC cancer cases diagnosed
during the study period underwent breast surgery. These
percentages are in accordance with reports from pre-
viously published studies in European countries such as
Ireland [21] (84% for the period 2004–2008), the United
Kingdom (72% in the year 2006) [22] and Switzerland
(over 90% for the period 2003–2005) [23].No surgical interventions were detected for about 17%
of the patients in our study. The fact that 60% of these
cases presented with a local stage at diagnosis (when
surgery is recommended by clinical practice guidelines)
[10] could mean that some of these women underwent
surgery in private centers before being attended in the
public system. This suggests an under-detection of sur-
gical cases in our study. If we add this group of patients
to the total surgical cases we did detect, our percentage
would probably be close to 90%, similar to those re-
ported in other series in the same time period [21,23].
Furthermore, the higher percentage of advanced tumor
stages among non-surgical, compared to surgical, patient
groups, suggests that the tumor stage collected by using
a simplification of the Disease Staging method [16] ad-
equately classified those patients considered as non-
surgical [24]. In fact, non-surgical, advanced disease
stage cases represent about 7.5% of all the breast cancers
in our study, similar to the percentage published by
other authors [25] and to the results obtained in a BC
cancer study carried out by the population cancer regis-
try in the Catalonian province of Girona (6.5% of women
were diagnosed at stage IV in 2005, unpublished data).
On the other hand, 82% of our patients presented with
local BC. Although this figure seems compatible with
the wide coverage of BC screening programs and with
the high survival (about 85% at 5 years) of BC patients
in Catalonia, it might be overestimated. In the Girona
registry, women with stage I-IIB represented just 73% of
the total (unpublished data). This discrepancy could be
explained by the fact that we discarded the ICD-9-CM
code 196.3 (involvement of lymph nodes in the axilla
and upper extremity) for local stage classification.
Breast-conserving surgery versus mastectomy
The percentage of women with BC treated by conserva-
tive surgery in Catalonia rose significantly between 2005
and 2011, mainly in the 50–69 year-old age group. These
figures (74% in the year 2011) are consistent with other
studies in Spain [26,27] and worldwide [23,28-30], where
reports ranged from 55% to 69%. On the other hand, the
United States (US) and Japan show a certain under-
utilization of this procedure, with percentages ranging
from 51% to 59% in the former [31,32] and just 36% in
the latter [33]. Differences in the survey periods, the pa-
tient selection criteria, the methods used, the screening
programs and the national health policies could all play
a role in explaining the differences in these results.
The rise of conservative surgery among regional stage
BC patients in Catalonia could be explained by the ad-
ministration of adjuvant treatment, mainly post-surgical
radiation therapy. Other relevant data found in this
study shows a generalization of conservative surgery in
most Catalonian health centers, with a rising preference
Table 2 Characteristics of breast cancer patients diagnosed in 2005, 2008 and 2011 in Catalonia, Spain, according to type of surgery
Conservative surgery Radical surgery
2005 2008 2011 2005 2008 2011
n (%) n (%) n (%) β* (95% CI) n (%) n (%) n (%) β* (95% CI)
Age
≤49 528 (26.2) 614 (26.3) 583 (23.7) −0.017 (−0.034; −0.001) 267 (28.0) 301 (34.0) 293 (33.8) 0.030 (0.008;0.053)
50- 69 1005 (49.8) 1229 (52.7) 1343 (54.5) 0.015 (0.006; 0.024) 339 (35.6) 282 (31.9) 299 (34.5) −0.006 (−0.027; 0.016)
≥ 70 485 (24.0) 490 (21.0) 537 (21.8) −0.016 (−0.034; 0.003) 347 (36.4) 302 (34.1) 275 (31.7) −0.023 (−0.044;-0.002)
Stage cp
Local 1849 (91.6) 2072 (88.8) 2039 (82.8) −0.016 (−0.020; −0.013) 864 (90.7) 722 (81.6) 646 (74.5) −0.033 (−0.040;-0.026)
Regional 153 (7.6) 250 (10.7) 398 (16.2) 0.128 (0.100; 0.157) 73 (7.7) 131 (14.8) 184 (21.2) 0.161 (0.122; 0.201)
Distant 16 (0.8) 11 (0.5) 26 (1.1) 0.064 (−0.047; 0.179) 16 (1.7) 32 (3.6) 37 (4.3) 0.141 (0.054; 0.230)
Charlson Comorbidity Index
No comorbidity 1718 (85.1) 1947 (83.5) 1995 (81.0) −0.008 (−0.013; −0.004) 772 (81.0) 704 (79.5) 679 (78.3) −0.006 (−0.013;0.002)
Low comorbidity 243 (12.0) 305 (13.1) 355 (14.4) 0.030 (0.005; 0.055) 132 (13.9) 135 (15.3) 130 (15.0) 0.013 (−0.024;0.050)
High comorbidity 57 (2.8) 81 (3.5) 113 (4.6) 0.082 (0.031; 0.134) 49 (5.1) 46 (5.2) 58 (6.7) 0.045 (−0.018;0.108)
Type of surgery
Tumorectomy/Partial mastectomy 2018 (100.0) 2333 (100.0) 2463 (100.0) - - - - - -
Simple mastectomy - - - - - - 812 (85.2) 757 (85.5) 719 (82.9) −0.004 (−0.011;0.002)
Radical mastectomy - - - - - - 124 (13.0) 107 (12.1) 110 (12.7) −0.005 (−0.045;0.306)
Subcutaneous mastectomy - - - - - - 17 (1.8) 21 (2.4) 38 (4.4) 0.157 (0.064; 0.254)
Lymph node removal 1556 (77.1) 1990 (85.3) 2122 (86.2) 0.016 (0.012; 0.021) 830 (87.1) 783 (88.5) 776 (89.5) 0.005 (−0.001;0.010)
Type of lymph node removal1
Simple 759 (48.8) 1349 (67.8) 1516 (71.4) 0.070 (0.061; 0.079) 528 (63.6) 559 (71.4) 526 (67.8) 0.015 (0.002;0.027)
Radical 797 (51.2) 641 (32.2) 606 (28.6) −0.082 (−0.097;-0.067) 302 (36.4) 224 (28.6) 250 (32.2) −0.018 (−0.042;0.007)
Hospital complexity
Low 309 (15.3) 422 (18.1) 466 (18.9) 0.034 (0.012; 0.055) 172 (18.0) 138 (15.6) 153 (17.6) −0.005 (−0.039;0.029)
Medium 892 (44.2) 1068 (45.8) 1193 (48.4) 0.015 (0.005; 0.026) 405 (42.5) 390 (44.1) 420 (48.4) 0.022 (0.005;0.039)
High 817 (40.5) 843 (36.1) 804 (32.6) −0.036 (−0.049;-0.023) 376 (39.5) 357 (40.3) 294 (33.9) −0.023 (−0.043;-0.004)
In-hospital deaths2 1 (0.0) 0 (0.0) 2 (0.1) 0.144 (−0.355; 0.749) 4 (0.4) 1 (0.1) 1 (0.1) −0.260 (−0.718; 0.088)
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Table 2 Characteristics of breast cancer patients diagnosed in 2005, 2008 and 2011 in Catalonia, Spain, according to type of surgery (Continued)
Discharge destination
Domicile 2008 (99.5) 2328 (99.8) 2451 (99.5) 0 (−0.001; 0.001) 943 (99.0) 872 (98.5) 848 (97.8) −0.002 (−0.004; 0.001)
With support 9 (0.4) 4 (0.2) 11 (0.4) 0.009 (−0.156; 0.178) 8 (0.8) 11 (1.2) 19 (2.2) 0.164 (0.032;0.304)
Other3 1 (0.0) 1 (0.0) 1 (0.0) −0.033 (−0.535; 0.469) 2 (0.2) 2 (0.2) 0 (0.0) −0.260 (−0.850;0.162)
Total4 2018 (67.9) 2333 (72.5) 2463 (74.0) 0.014 (0.009; 0.019) 953 (32.1) 885 (27.5) 867 (26.0) −0.035 (−0.048;-0.022)
*β is the slope of the log-binomial model used to measure the temporal trend; 95% CI: 95%Confidence Interval; In bold, statistically significant; 1Percentages were calculated taking into account the total number of
lymph node removal; 2Mortality within 30 days after admission; 3Includes hospital mortality during hospitalization (in-hospital mortality); 4Percentages were calculated taking into account the total number of surgical
patients in the respective years.
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Table 3 Mastectomized breast cancer patients with reconstructive surgery diagnosed in 2005, 2008 and 2011 in
Catalonia, Spain
Radical surgery
2005 2008 2011
n (%) n (%) n (%) β* (95% CI)
Age
≤49 99 (60.7) 147 (65.6) 121 (61.1) 0.000 (−0.026; 0.026)
50 - 69 56 (34.4) 68 (30.4) 69 (34.8) 0.004 (−0.045; 0.054)
≥ 70 8 (4.9) 9 (4.0) 8 (4.0) −0.032 (−0.197; 0.132)
Stage
Local 144 (88.3) 173 (77.2) 148 (74.7) −0.030 (−0.047;-0.012)
Regional 14 (8.6) 48 (21.4) 42 (21.2) 0.113 (0.038; 0.191)
Distant 5 (3.1) 3 (1.3) 8 (4.0) 0.071 (−0.137; 0.290)
Charlson Comorbidity Index
No comorbidity 143 (87.7) 200 (89.3) 177 (89.4) 0.003 (−0.009; 0.015)
Low comorbidity 15 (9.2) 21 (9.4) 18 (9.1) −0.002 (−0.110; 0.107)
High comorbidity 5 (3.1) 3 (1.3) 3 (1.5) −0.132 (−0.400; 0.118)
Type of surgery
Simple mastectomy 129 (38.7) 175 (78.1) 149 (75.3) −0.008 (−0.027; 0.010)
Radical mastectomy 17 (8.6) 30 (13.4) 13 (6.6) −0.067 (−0.168; 0.034)
Subcutaneous mastectomy 17 (52.8) 19 (8.5) 36 (18.2) 0.117 (0.021; 0.216)
Type of reconstruction
Immediate 126 (77.3) 192 (85.7) 187 (94.4) 0.033 (0.020; 0.047)
Delayed 37 (22.7) 32 (14.3) 11 (5.6) −0.213 (−0.307; −0.124)
Hospital complexity
Low 26 (16.0) 40 (17.9) 31 (15.7) −0.004 (−0.081; 0.073)
Medium 47 (28.8) 77 (34.4) 85 (42.9) 0.068 (0.021; 0.115)
High 90 (55.2) 107 (47.8) 82 (41.4) −0.048 (−0.084;-0.012)
Total1 163 (17.1) 224 (25.3) 198 (22.8) 0.044 (0.016; 0.073)
*β is the slope of the log-binomial model used to measure the temporal trend; 95% CI: 95% Confidence Interval; In bold, statistically significant; 1Percentages were
calculated taking into account the total number of mastectomized patients in the respective years.
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and low complexity. The spread of conservative treat-
ment favors equity, regardless of the geographic area
where patients live.
As noted by other authors [34,35], removal of lym-
phatic structures has increased significantly among pa-
tients treated with BCS, with a rise in simple lymph
node excision. This finding is closely related to the im-
plementation of sentinel lymph node biopsy (SLNB),
which spread in Catalonia over the course of the study
period.
In terms of mastectomy, our results for 2005–2011
showed a significant decrease among women treated
surgically, in line with data from the European euso-
maDB database [36], but in contrast to the trend in
the US between 2004 and 2008 [37,38]. Moreover,mastectomy rates in the Catalonian population were
slightly lower than those reported in most European
countries [30,32], Canada [39], the US [32,37] and Japan
[33]. This could suggest a slight underestimation in our
study, due to a failure to consider those patients initially
treated with conservative surgery who received a mast-
ectomy during a 12-month follow-up period. It should
also be noted that (as in our study) most of the cases in-
volved in all these studies were in early breast cancer
stages (0, I and II).
An upward trend in mastectomy rates among women
under 50 years of age is consistent with other studies
[38,39], and may be explained by several factors, inclu-
ding the higher stage disease at diagnosis, the presence
of more biologically aggressive tumors, the higher risk of
recurrence over the patients’ lifetime, the availability of
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aesthetic requirements, patient preference and other in-
tangible factors.
In accordance with other series, patients treated with
radical surgery are older and have greater comorbidity
compared to those treated conservatively [27,32].
Reconstructive surgery after mastectomy
Worldwide, post-mastectomy reconstruction rates have
increased over the last decade due to a number of fac-
tors, but the procedure is still performed only in a mi-
nority of patients. The relatively young age of patients,
the local stage of their tumors, the null or low comor-
bidity, and patient access to more specialized health
centers are all recognized as limiting factors in breast re-
construction [40,41].
In our case, there was a considerable and general in-
crease in reconstructive surgery during the seven-year
period, similar to the rise observed in England [42], and
in contrast to the trends reported in Canada [39,40] and
Australia [41] (historically low), and in the US [43,44]
(where rates are higher than ours). The rise of breast re-
construction in Catalonia occurred basically due to im-
mediate reconstructive surgery, because delayed breast
reconstruction dropped significantly in the study period.
Methodological strengths and limitations
Our study has several strengths that should be considered.
First, the starting point was, the HDD, a population-based
information source that has been proved valuable and re-
liable to carry out clinical and epidemiological studies. Se-
cond, the use of ASEDAT software (previously validated)
[12], allowed us to identify patients from the first episode
of breast cancer care, essentially equivalent to the inci-
dence date. The number of incident breast cancer cases in
2008 in Catalonia (n = 3849) was similar to the estimated
number from the Catalonian population-based cancer
registries (n = 3907) [8], reinforcing the validity of the
methodology used. Third, breast cancer is basically a sur-
gical disease that requires hospitalization, a fact which
favors the availability of comprehensive information for
primary and reconstructive surgery, because cases are
followed for a minimum of 12 and a maximum of
24 months. Finally, information about the application of
primary and secondary ICD-9-CM diagnosis and proce-
dures codes allowed us to determine comorbidity and esti-
mate cancer stage, in addition to knowing the surgical
techniques implemented.
As for the limitations, we should mention firstly the
intrinsic weaknesses of the study design. This is a
descriptive study in a database used by Catalonian
hospitals, so there could be some variability in coding
practices between centers and professionals and the
ICD-9-CM changes that happened over the study. Forinstance, we found some specific deficiencies, such as
the lack of any specific ICD-9-CM codes for the most
recent techniques, such as SLNB, which prevented us
from assessing the impact of its implementation simul-
taneously with the lymph node dissection.
Secondly, the underestimation of surgical cases by the
lack of information on discharges in private hospitals.
Thirdly, the lack of relevant information for tumor stage
in the HDD, although we tried to mitigate this problem
by creating a proxy for the disease stage based on the
ICD-9-CM (Additional file 1: Table S2a) [16,17]. Despite
not having been validated in a sample of patient’s me-
dical records, as we mentioned previously, this method
seems to have properly delimited the advanced neo-
plastic disease but overestimated local disease by about
10%. Our results, agree with some validation studies
[17,45,46], suggests caution when interpreting the re-
sults, given the likelihood of overestimating local stages
versus advanced stages.
Despite all the aforementioned limitations, this study
may be considered an interesting methodological contri-
bution to automated studies of quality indicators from
clinical and administrative databases in Catalonia, with
regard to surgical procedures for invasive breast cancer.
Conclusions
In summary, the use of HDD linked to the ASEDAT soft-
ware allowed us to estimate the incidence and to evaluate
breast cancer surgical treatment in Catalonia. Around
80% of women diagnosed with breast cancer over the
study periods were treated by conservative surgery. This
trend seems to be consolidating in women aged 50–69
and corresponds to the pattern observed in most other
European countries. The increase of simple lymph node
removal in surgical patients suggests an increase in the
practice of sentinel lymph node biopsy. Among the mas-
tectomized patients, immediate breast reconstructions
have risen significantly from 2005 to 2011.
Additional file
Additional file 1: Table S1. Contains the ICD-9-CM 6th edition codes
associated with different types of surgery in breast cancer; Table S2a
contains the staging classification codes from ICD-9-CM; Table S2b
contains the ICD-9-CM codes related to the presence of metastases.
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